secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coya Therapeutics, Inc. (COYA)
CIK:        0001835022
Form:       8-K
Filed at:   2024-01-19T23:59:59+00:00
Accession:  0001193125-24-010775
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Coya Therapeutics reports $32.6M cash at Dec 31, 2023; receives $7.5M from Dr. Reddy's in Jan 2024
--------------------------------------------------------------------------------

- Cash and equivalents $32.6M as of Dec 31, 2023; pro forma $40.1M after $7.5M received from Dr. Reddy's in Jan 2024.
- Milestone payments: $4.2M upon FDA acceptance of IND for COYA 302 (ALS) and $4.2M upon first patient dosed in Phase 2.
- Anticipates IND filing in H1 2024 and first patient dosing in H2 2024 for COYA 302 in ALS.
- Company expects current cash runway to fund operations into 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835022/000119312524010775/0001193125-24-010775-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835022/000119312524010775/d732822d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-010775

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer